Quantitative Gel Zymography Reappraised for Matrix Metalloproteinases
|
By LabMedica International staff writers Posted on 29 Oct 2014 |

Image: The gel zymography separation of matrix metalloproteinases (MMPs) on a 7.5% polyacrylamide gel (Photo courtesy of the Italian National Research Council).
A reappraisal of quantitative gel zymography technique for matrix metalloproteinases (MMPs) in human plasma has been used for comparison with commercially available enzyme-linked immunosorbent assay (ELISA).
The determination of MMPs is relevant in numerous pathophysiological conditions, as imbalanced MMP activity is associated with many clinical conditions, including cardiovascular diseases, especially if associated with extracellular matrix remodeling, but the results obtained are closely linked to the method used and are not directly comparable.
Scientists at the Italian National Research Council (CNR; Pisa, Italy) obtained heparinized blood samples from 25 volunteers. The samples were centrifuged and the serum stored in aliquots at −80 °C. Gel zymography was performed based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and on the use of gelatin 0.5% as substrate for detection of MMP enzymatic activity. Gelatinolytic activities were detected as unstained bands against the background of Coomassie Blue stained gelatin. In order to quantify the concentrations of the analyzed protein in the unknown samples, a dose-response curve was built in each run.
Total MMP-9 was measured in diluted plasma by specific immunometric assay (R&D Systems; Minneapolis, MN, USA), previously standardized. The working range was 0.19 ng/mL to 16 ng/mL, the sensitivity was 0.05 ± 0.01 ng/mL, and the within-assay variability was 414.3 ± 23.5 ng/mL (5.7%), while the between-assay variability was less than 15%. The concentration of total MMP-9 was measured in parallel using the zymography and ELISA for comparison purposes.
The results obtained by gel zymography analysis of human blood samples using different acrylamide/bis acrylamide ratios indicated that 7.5% gels are the more suitable for visualizing MMP-9 forms. In all conditions, four bands with gelatinolytic activity are found: MMP-9 dimers, MMP-9– tissue inhibitor of metalloproteinase1 (TIMP-1) complex, MMP-9, and MMP-2. The time course of the proteolytic activity of MMPs indicated 16 to 24 hours as optimal incubation time and these optimal parameters were used for routine assay. A linear positive correlation was found between the MMP-9 values of zymography and ELISA with the ELISA values significantly lower than those obtained with zymography.
The authors concluded that the main advantage of gel zymography is that it allows visualization of both the latent and active forms of gelatinases. The presence of MMP dimers and MMP/TIMP complexes in the plasma samples, revealed by gel zymography, could thoroughly characterize the role of MMP in associated diseases. Gel zymography allows separation and visualization of MMP-2 bands, so both MMP-2 and MMP-9 can be determined in the same run from a single biological sample. The study was published in the September 2014 issue of the Journal of Clinical Laboratory Analysis.
Related Links:
Italian National Research Council
R&D Systems
The determination of MMPs is relevant in numerous pathophysiological conditions, as imbalanced MMP activity is associated with many clinical conditions, including cardiovascular diseases, especially if associated with extracellular matrix remodeling, but the results obtained are closely linked to the method used and are not directly comparable.
Scientists at the Italian National Research Council (CNR; Pisa, Italy) obtained heparinized blood samples from 25 volunteers. The samples were centrifuged and the serum stored in aliquots at −80 °C. Gel zymography was performed based on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and on the use of gelatin 0.5% as substrate for detection of MMP enzymatic activity. Gelatinolytic activities were detected as unstained bands against the background of Coomassie Blue stained gelatin. In order to quantify the concentrations of the analyzed protein in the unknown samples, a dose-response curve was built in each run.
Total MMP-9 was measured in diluted plasma by specific immunometric assay (R&D Systems; Minneapolis, MN, USA), previously standardized. The working range was 0.19 ng/mL to 16 ng/mL, the sensitivity was 0.05 ± 0.01 ng/mL, and the within-assay variability was 414.3 ± 23.5 ng/mL (5.7%), while the between-assay variability was less than 15%. The concentration of total MMP-9 was measured in parallel using the zymography and ELISA for comparison purposes.
The results obtained by gel zymography analysis of human blood samples using different acrylamide/bis acrylamide ratios indicated that 7.5% gels are the more suitable for visualizing MMP-9 forms. In all conditions, four bands with gelatinolytic activity are found: MMP-9 dimers, MMP-9– tissue inhibitor of metalloproteinase1 (TIMP-1) complex, MMP-9, and MMP-2. The time course of the proteolytic activity of MMPs indicated 16 to 24 hours as optimal incubation time and these optimal parameters were used for routine assay. A linear positive correlation was found between the MMP-9 values of zymography and ELISA with the ELISA values significantly lower than those obtained with zymography.
The authors concluded that the main advantage of gel zymography is that it allows visualization of both the latent and active forms of gelatinases. The presence of MMP dimers and MMP/TIMP complexes in the plasma samples, revealed by gel zymography, could thoroughly characterize the role of MMP in associated diseases. Gel zymography allows separation and visualization of MMP-2 bands, so both MMP-2 and MMP-9 can be determined in the same run from a single biological sample. The study was published in the September 2014 issue of the Journal of Clinical Laboratory Analysis.
Related Links:
Italian National Research Council
R&D Systems
Latest Clinical Chem. News
- Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
- Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
- Blood Test Detects Testicular Cancer Missed by Standard Markers
- Routine Blood Tests Identify Biomarkers Linked to PTSD
- Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
- Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
- Label-Free Microfluidic Device Enriches Tumor Cells and Clusters from Pleural Effusions
- Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
- Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
- Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
- Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
- AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
Channels
Molecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








